Business Context and Reporting Period
This Form 8-K Current Report covers events occurring on September 19, 2025, and September 23, 2025, for Faraday Future Intelligent Electric Inc. (FFAI). The filing details a material investment in Qualigen Therapeutics, Inc., the results of a Special Meeting of Stockholders held on September 19, 2025, and subsequent amendments to the Company's Certificate of Incorporation.
Key Financial Metrics and Transaction Details
Investment in Qualigen Therapeutics:
- Total Investment: Approximately $40.7 million.
- Payment Method: Cash, USDC (cryptocurrency stablecoin), and/or other cryptocurrencies.
- Assets Acquired: Qualigen Common Stock at $2.246 per share and/or Series B Preferred Stock at $1,000.00 per share.
- Closing Date: Expected on or about September 29, 2025.
Stockholder Voting Results (Special Meeting):
- Quorum: 45.31% of voting shares present.
- Proposal 1 (Share Authorization): Approved. Authorized Common Stock increased to 232,470,985 shares; Preferred Stock increased to 17,931,000 shares.
- Proposal 2 (Private Placement): Approved. Issuance of Class A Common Stock to holders of convertible notes and warrants.
- Proposal 3 (Name Change): Not Approved. Proposal to change name to "Faraday Future AI Electric Vehicle Inc." failed to receive a majority vote.
- Proposal 4 (Stock Incentive Plan): Approved. 2021 Plan increased by 9,500,000 shares.
- Proposal 5 (Adjournment): Approved.
Financial Performance: The filing text does not provide revenue, profit, cash flow, margins, debt, or liquidity metrics for the reporting period.
Material Changes and Governance
Qualigen Governance Rights:
- Board Representation: FFAI will appoint two directors immediately upon closing, with rights to designate additional nominees proportionate to beneficial ownership. One FFAI designee will serve as Chairperson.
- Management Control: Upon closing, FFAI-designated individuals will be appointed as Qualigen's Co-Chief Executive Officer and Chief Financial Officer.
- Registration Rights: Qualigen must file a registration statement within 45 days of the signing date to register the securities for resale.
- Stockholder Approval: Qualigen must obtain stockholder approval by October 29, 2025 (or November 28, 2025 if reviewed by the SEC). If not obtained, Qualigen must hold additional meetings every 90 days until approval is secured.
Corporate Structure Changes:
- Authorized Shares: Increased total authorized shares from 180,145,313 to 250,401,985.
- Series A Preferred Stock: Eliminated following automatic redemption; the share resumed status as authorized but unissued preferred stock.
Outlook, Risks, and Contingencies
Contingencies:
- The closing of the Qualigen investment is subject to customary closing conditions.
- Qualigen's obligation to obtain stockholder approval is a critical contingency; failure to do so triggers a mandatory cycle of additional stockholder meetings.
Risks and Unusual Items:
- Cryptocurrency Payment: The investment involves payment via USDC and other cryptocurrencies, introducing volatility and regulatory risks associated with digital assets.
- Preferred Stock Terms: The Series B Preferred Stock includes redemption rights upon "Triggering Events" and a potential retroactive dividend increase to 15% per annum.
- Failed Name Change: The rejection of the name change proposal indicates potential stockholder resistance to the proposed strategic rebranding.
Management Commentary: The filing does not contain explicit forward-looking guidance or management commentary beyond the transaction terms and voting results.
Key Facts for Investor Verification
- Verify the source and valuation of the $40.7 million investment capital, specifically the portion paid in cryptocurrency.
- Monitor Qualigen's progress in obtaining stockholder approval by the October 29, 2025 deadline.
- Review the specific "Triggering Events" defined in the Certificate of Designation that could force Qualigen to redeem the Series B Preferred Stock.
- Assess the impact of the failed name change proposal on the company's strategic direction and market perception.
- Confirm the appointment of FFAI-designated executives to Qualigen's CEO and CFO roles post-closing.